Literature DB >> 2883391

The myocardium in ankylosing spondylitis. A clinical, echocardiographic, and histopathological study.

D A Brewerton, D G Gibson, D H Goddard, T J Jones, R B Moore, C T Pease, P A Revell, L M Shapiro, K V Swettenham.   

Abstract

Cardiac function was investigated in men with ankylosing spondylitis (AS) age 21-65 years who had no cardiorespiratory symptoms or known abnormalities of heart or lungs. Chest radiographs and standard electrocardiograms were normal in 73 of 74 subjects. In echocardiographs of 30 men, left atrial size and left ventricular cavity size and wall thickness were normal. Minor abnormalities in the valve roots were present in 3 older men. Early diastolic abnormalities of the left ventricle were demonstrated in 16 of 30 subjects. This finding was confirmed by repetition of the echocardiography a year later in 15 subjects and by comparison of 11 probands with their healthy brothers. Myocardial tissue obtained at necropsy from 28 AS patients without ischaemic or valvular heart disease or hypertension was studied. A mild, diffuse increase of interstitial connective tissue was seen but there was no inflammatory change or amyloid. Computerised image analysis showed 30.7% interstitial reticulin compared with 17.7% in age/sex matched controls (p less than 0.0001).

Entities:  

Mesh:

Year:  1987        PMID: 2883391     DOI: 10.1016/s0140-6736(87)92268-9

Source DB:  PubMed          Journal:  Lancet        ISSN: 0140-6736            Impact factor:   79.321


  22 in total

Review 1.  The heart in ankylosing spondylitis.

Authors:  T W O'Neill; B Bresnihan
Journal:  Ann Rheum Dis       Date:  1992-06       Impact factor: 19.103

2.  Ventricular Tacyhcardia in A Patient with A Previous History of Endocarditis and Ankylosan Spondylitis: A Challenging Case.

Authors:  Yavuzer Koza; Muhammed Hakan Taş; Ziya Şimşek; Fuat Gündoğdu
Journal:  Eurasian J Med       Date:  2016-10

3.  Why the joint, why the eye?

Authors:  A Keat
Journal:  Clin Rheumatol       Date:  1996-01       Impact factor: 2.980

4.  Evaluation of cardiac function by two-dimensional speckle tracking echocardiography in ulcerative colitis patients.

Authors:  Altug Cincin; Murat Sunbul; Tarık Kivrak; Halil Atas; Ibrahim Sari; Kursat Tigen; Tarik Kani; Hakan Akin; Nese Imeryuz; Yelda Basaran
Journal:  Dig Dis Sci       Date:  2014-07-15       Impact factor: 3.199

5.  Heart conduction disturbance: an HLA-B27 associated disease.

Authors:  A J Peeters; S ten Wolde; M I Sedney; R R de Vries; B A Dijkmans
Journal:  Ann Rheum Dis       Date:  1991-06       Impact factor: 19.103

6.  Susceptibility to ankylosing spondylitis: no evidence for the involvement of transforming growth factor beta 1 (TGFB1) gene polymorphisms.

Authors:  M van der Paardt; J B A Crusius; M A García-González; B A C Dijkmans; A S Peña; I E van der Horst-Bruinsma
Journal:  Ann Rheum Dis       Date:  2005-04       Impact factor: 19.103

7.  Myocardial dysfunction in ankylosing spondylitis.

Authors:  B A Gould; J Turner; D H Keeling; P Hickling; A J Marshall
Journal:  Ann Rheum Dis       Date:  1992-02       Impact factor: 19.103

8.  Left ventricular systolic dysfunction in patients with ankylosing spondylitis without clinically overt cardiovascular disease by speckle tracking echocardiography.

Authors:  Nilgun Ustun; Mustafa Kurt; Alper Bugra Nacar; Hacer Paksoy Karateke; Hayal Guler; Ayse Dicle Turhanoglu
Journal:  Rheumatol Int       Date:  2014-09-19       Impact factor: 2.631

9.  Ankylosing spondylitis and heart abnormalities: do cardiac conduction disorders, valve regurgitation and diastolic dysfunction occur more often in male patients with diagnosed ankylosing spondylitis for over 15 years than in the normal population?

Authors:  Florian Brunner; Andres Kunz; Ulrich Weber; Rudolf Kissling
Journal:  Clin Rheumatol       Date:  2005-10-25       Impact factor: 2.980

10.  Management and evaluation of extra-articular manifestations in spondyloarthritis.

Authors:  Irene E van der Horst-Bruinsma; Michael T Nurmohamed
Journal:  Ther Adv Musculoskelet Dis       Date:  2012-12       Impact factor: 5.346

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.